Pfizer Covid-19 vaccine safety: What two new studies found

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
0:00
play article
Subscribers can listen to this article
A vial of the Pfizer BioNTech vaccine for coronavirus treatment. Spain has exceeded 32 million people vaccinated with the full schedule. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)
A vial of the Pfizer BioNTech vaccine for coronavirus treatment. Spain has exceeded 32 million people vaccinated with the full schedule. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)
Marcos del Mazo/ contributor

The Covid-19 vaccine by Pfizer-BioNTech carries a very small risk of inflammation of the heart muscle, known as myocarditis, new data from Israel has revealed. A separate cohort, however, found that the risk of this heart problem was substantially higher after infection with the virus than after vaccination.

Myocarditis generally occurs around three to four days after vaccination and typically after the second dose. The rare side effect has most commonly been seen in adolescent boys and young men.

"In this study in a nationwide mass vaccination setting, the (Pfizer) vaccine was… associated with an excess risk of myocarditis" – an extra 2.7 cases of myocarditis for every 100 000 people in the vaccinated group, compared with the unvaccinated one, they wrote. Most of these events were mild and temporary.

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism. You can cancel any time.
Subscribe
Already a subscriber? Sign in
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
30% - 9647 votes
No
70% - 22670 votes
Vote